Insmed (INSM) reported a Q2 loss Thursday of $0.06 per share, narrowing from a loss of $1.70 a year earlier.
Analysts polled by FactSet expected a loss of $0.69.
Revenue for the quarter ended June 30 was $425.5 million, up from $107.4 million a year earlier.
An analyst polled by FactSet expected $425.5 million.
For 2026, Insmed raised its Brinsupri revenue guidance to a range of $1.25 billion to $1.40 billion from its prior outlook of at least $1 billion, while reiterating Arikayce revenue guidance of $450 million to $470 million.
Insmed shares were over 21% higher in premarket activity Thursday.
Price: $120.60, Change: $+21.58, Percent Change: +21.79%